Avila Therapeutics Presents New Btk Inhibitor Data at Federation of Clinical Immunology Societies Me…
We recommend:
Clinical Candidate, AVL-292, Demonstrates Efficacy in Preclinical Models of Rheumatoid Arthritis
BOSTON & WALTHAM, Mass.–(BUSINESS WIRE)–Jun 28, 2010 - Avila Therapeutics™, Inc. , a ergonomics troupe development targeted covalent drugs that dainty diseases done protein silencing , nowadays proclaimed results of presymptomatic studies demonstrating that its clinical prospect, AVL-292, powerfully inhibits B cubicle receptor signal, and demonstrates efficaciousness in a gnawer example of creaky arthritis. These new information were presented Saturday, June 26, 2010 at the Federation of Clinical Immunology Societies (FOCIS) 2010 yearly merging in Boston, MA.
AVL-292 is a fresh, orally useable, covalent dose that targets Bruton’s tyrosine kinase (Btk). Inhibition of Btk is a bright new access to handling of diseases that are impelled by B cells, which are parting of the resistant organization. AVL-292 bonds selectively and covalently with Btk to exclude refine and muteness its activeness. This unparalleled mechanics of fulfill confers greater objective selectivity and a thirster length of execute than is distinctive of established belittled particle drugs.
Btk plays a important character in the activating of pattern B lymphocytes and contributes to the proliferation and selection of B cubicle lymphomas. AVL-292, with its power to irreversibly suppress and hush Btk, may map a new best-in-class remedy alternative for the discussion of autoimmune diseases such as arthritic arthritis, as fountainhead as B cell-related haematological cancers, including non-Hodgkin lymphoma (NHL) and B cellphone continuing lymphocytic leucaemia (B-CLL).
In an viva presentment at FOCIS entitled “A Novel Covalent Inhibitor of Btk Inhibits B Cell Receptor Signaling and Demonstrates Efficacy in CIA Rheumatoid Arthritis Model”, Erica Evans, Ph.D., Senior Scientist, Avila Therapeutics, presented information from presymptomatic studies that evaluated the efficaciousness of AVL-292 in the sneak collagen-induced arthritis manakin. Highlights of the information evidence:
”We are activated to portion these information with the clinical and explore community at FOCIS,” aforementioned Juswinder Singh, Ph.D., Avila’s Founder and Chief Scientific Officer. “These results prove identical heavy disease-modifying effects of AVL-292 in both cautionary and cure models of creaky arthritis. In concurrence with the prophylactic examination Avila Therapeutics has realised, the efficaciousness information furnish exciting substantiation for this platform as we procession AVL-292 into clinical studies this year.”
The covalent soldering mechanics of Avila Therapeutics’ drugs has unequalled properties to efficaciously ?secretiveness’ disease-causing proteins. Avila drugs demonstrate a hard and long-suffering ?adhesion’ – olympian the more irregular ?dressing’ of schematic drugs – to all closed refine the activeness of, and secrecy, a disease-causing protein. Avila’s covalent drugs get unequalled alterative benefits because they are finely targeted, are efficacious against mutations and birth farseeing length of activeness.
About Avila Therapeutics™, Inc.
Avila focuses on invention and growing of targeted covalent drugs to attain best-in-class outcomes that cannot be achieved done traditional chemistries. This attack is called “protein silencing”. The party’s production grapevine has been reinforced exploitation its proprietorship Avilomics™ program and is presently focussed on viral contagion, cancer and autoimmune disease. Avila is funded by lead guess majuscule firms: Abingworth, Advent Venture Partners, Atlas Venture, Novartis Option Fund, and Polaris Venture Partners. For extra data, delight sojourn http://www.avilatx.com .
Contact: Media:
Latest Clinical Trial Results…
Today besellers:
Leave a Reply